Azitra
AZTR

$0.5851

2.48%

Market Cap: $4.46M

About: Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.

Employees: 10

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

3.28% less ownership

Funds ownership: 5.35% [Q1] → 2.07% (-3.28%) [Q2]

33% less funds holding

Funds holding: 12 [Q1] → 8 (-4) [Q2]

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

82% less capital invested

Capital invested by funds: $316K [Q1] → $58.5K (-$258K) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for AZTR.

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about AZTR published over the past 30 days

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for topically applied ATR-04 to treat moderate to severe Epidermal Growth Factor Receptor inhibitor (EGFRi) associated dermal toxicity. Francisco Salva, Azitra's CEO, stated, "We are thrilled to announce the FDA has grant.

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it announced today that Travis Whitfill, COO, will present an overview of the Company at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 9-11, 2024. Company management will also be participating in one-on-one meetings during the conference. The on-demand presentation will be available for viewing beginning September 9 at 7:00 a.m. ET. An ar.

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a precision dermatology company, announced that it has initiated dosing the first patient in its Phase 1b clinical trial evaluating ATR-12 for the treatment of Netherton syndrome. The study is designed to enroll approximately 12 adult patients with twice-daily treatment for 14 days, with primary endpoints focusing on safety and tolerability, and secondary and exploratory endpoints assessing efficacy signals and biomarkers. Az.

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the clearance of an investigational new drug (IND) application to U.S. Food and Drug Administration (FDA) for a first-in-human Phase 1/2 clinical study of ATR-04 for moderate to severe EGFRi associated dermal toxicity. Francisco Salva, Azitra's CEO, stated, "We are delighted to announce a new IND cl.

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it has successfully screened the first patient in its Phase 1b clinical trial evaluating ATR-12 for the treatment of Netherton syndrome. The patient is scheduled to initiate treatment by the end of the month. The study is designed to enroll approximately 12 adult patients with twice-daily treatment for 14 days, with primary endpoints focusing on safety and tolerability, and secon.

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing m.

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering

BRANFORD, Conn.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: AZITRA, INC. ANNOUNCES CLOSING OF $10.0 MILLION PUBLIC OFFERING Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the closing of its previously announced public offering of an aggregate of 6,665,000 shares of its common.

CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering

You.com Announces Strategic Collaboration With Moesif to Drive Productivity and Power Usage-Based Billing

PALO ALTO, Calif.--(BUSINESS WIRE)--You.com, the AI-powered productivity engine, today announced a new strategic collaboration with Moesif, a leading provider of monetization and usage-based billing for AI and API products. Under this collaboration, Moesif employees will use you.com's AI Assistants to drive productivity through fast and accurate research and analysis, complex problem-solving, content creation, and more. You.com will use Moesif to monetize its AI APIs through usage-based billing.

You.com Announces Strategic Collaboration With Moesif to Drive Productivity and Power Usage-Based Billing

Wingspire Equipment Finance's $12 Million Funding Initiative to Propel Tier 1 Aerospace Manufacturer Capabilities

TUSTIN, Calif.--(BUSINESS WIRE)--Wingspire Equipment Finance is proud to announce a $12,000,000 equipment financing to a leading aerospace manufacturing company. The Tier 1 aerospace manufacturer is known for producing specialized components and its capabilities in sheet metal fabrication, precision machining, and complex assemblies. Through a collaborative effort with the company and its private equity sponsor, Wingspire Equipment Finance developed a solution tailored to their unique requireme.

Wingspire Equipment Finance's $12 Million Funding Initiative to Propel Tier 1 Aerospace Manufacturer Capabilities

Why Is Azitra (AZTR) Stock Down 75% Today?

Azitra (NYSEMKT: AZTR ) stock is falling hard on Wednesday morning after the biopharmaceutical company's shares underwent a massive rally yesterday. Azitra stock is down 75.2% as of Wednesday morning.

Why Is Azitra (AZTR) Stock Down 75% Today?

See News Rankings